Wells Fargo & Company MN increased its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 10.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,716,647 shares of the exchange traded fund’s stock after buying an additional 156,483 shares during the quarter. Wells Fargo & Company MN’s holdings in SPDR S&P Biotech ETF were worth $164,576,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Nvwm LLC grew its stake in shares of SPDR S&P Biotech ETF by 2.5% during the 2nd quarter. Nvwm LLC now owns 21,631 shares of the exchange traded fund’s stock worth $2,059,000 after purchasing an additional 526 shares during the period. WealthPLAN Partners LLC grew its stake in shares of SPDR S&P Biotech ETF by 4.9% during the 2nd quarter. WealthPLAN Partners LLC now owns 12,049 shares of the exchange traded fund’s stock worth $1,147,000 after purchasing an additional 560 shares during the period. BB&T Securities LLC grew its stake in shares of SPDR S&P Biotech ETF by 5.8% during the 2nd quarter. BB&T Securities LLC now owns 11,533 shares of the exchange traded fund’s stock worth $1,097,000 after purchasing an additional 635 shares during the period. Cypress Capital Management LLC WY grew its stake in shares of SPDR S&P Biotech ETF by 51.8% during the 2nd quarter. Cypress Capital Management LLC WY now owns 2,065 shares of the exchange traded fund’s stock worth $197,000 after purchasing an additional 705 shares during the period. Finally, Boothe Investment Group Inc. grew its stake in shares of SPDR S&P Biotech ETF by 2.5% during the 3rd quarter. Boothe Investment Group Inc. now owns 29,111 shares of the exchange traded fund’s stock worth $2,791,000 after purchasing an additional 708 shares during the period.

Shares of NYSEARCA XBI opened at $80.78 on Friday. SPDR S&P Biotech ETF has a 12 month low of $76.37 and a 12 month high of $101.55.

TRADEMARK VIOLATION NOTICE: “Wells Fargo & Company MN Raises Position in SPDR S&P Biotech ETF (XBI)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2018/11/10/wells-fargo-company-mn-raises-position-in-spdr-sp-biotech-etf-xbi.html.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Article: What is Cost of Capital?

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.